Skip to main
ANIX
ANIX logo

ANIX Stock Forecast & Price Target

ANIX Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Anixa Biosciences Inc. has established a strong intellectual property position through its patent for CAR-T technology, which bolsters its competitive advantage in the biotechnology sector. The completion of the final patient visits in its Phase 1 breast cancer vaccine trial marks a significant clinical milestone, with preliminary data indicating over 70% of participants achieving a desired immune response and acceptable safety levels. Additionally, the company's dual approach to oncology, focusing on both preventative measures in high-risk individuals and therapeutic methods for existing cancer patients, enhances its potential for innovative cancer control with reduced side effects compared to traditional therapies, positioning it favorably in the immuno-oncology landscape.

Bears say

Anixa Biosciences Inc. is facing challenges due to its limited revenue streams and reliance on developmental-stage products, which often require significant investment without guaranteed returns. The company’s pursuit of complex therapeutic developments in oncology is compounded by high research and development costs, creating financial strain and uncertainty regarding future profitability. Additionally, its dependency on successful outcomes in clinical trials poses further risk, as setbacks in these trials could lead to substantial declines in stock performance.

ANIX has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Anixa Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Anixa Biosciences Inc (ANIX) Forecast

Analysts have given ANIX a Strong Buy based on their latest research and market trends.

According to 3 analysts, ANIX has a Strong Buy consensus rating as of Nov 8, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Anixa Biosciences Inc (ANIX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.